Opaleye Management Inc. Buys 35,000 Shares of Harrow Health (NASDAQ:HROW) Stock

Harrow Health (NASDAQ:HROW) major shareholder Opaleye Management Inc. bought 35,000 shares of the firm’s stock in a transaction on Friday, June 19th. The stock was acquired at an average cost of $5.58 per share, with a total value of $195,300.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Opaleye Management Inc. also recently made the following trade(s):

  • On Tuesday, June 2nd, Opaleye Management Inc. bought 19,400 shares of Harrow Health stock. The stock was acquired at an average cost of $5.69 per share, with a total value of $110,386.00.
  • On Thursday, June 4th, Opaleye Management Inc. bought 50,000 shares of Harrow Health stock. The stock was acquired at an average cost of $5.88 per share, with a total value of $294,000.00.
  • On Wednesday, May 20th, Opaleye Management Inc. bought 1,500 shares of Harrow Health stock. The stock was acquired at an average cost of $4.49 per share, with a total value of $6,735.00.
  • On Friday, May 22nd, Opaleye Management Inc. acquired 25,900 shares of Harrow Health stock. The shares were purchased at an average cost of $5.31 per share, with a total value of $137,529.00.

NASDAQ:HROW opened at $5.33 on Friday. The stock has a market cap of $146.80 million, a P/E ratio of -5.67 and a beta of 0.87. Harrow Health has a one year low of $3.33 and a one year high of $8.99. The company has a fifty day moving average price of $5.30 and a 200 day moving average price of $5.65. The company has a debt-to-equity ratio of 1.19, a current ratio of 1.95 and a quick ratio of 1.65.

Harrow Health (NASDAQ:HROW) last released its earnings results on Monday, May 11th. The company reported ($0.50) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.45). The company had revenue of $11.82 million for the quarter, compared to analyst estimates of $10.14 million. Harrow Health had a negative net margin of 47.54% and a negative return on equity of 32.90%. As a group, equities research analysts anticipate that Harrow Health will post -0.47 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in Harrow Health by 0.9% during the 1st quarter. BlackRock Inc. now owns 469,275 shares of the company’s stock valued at $1,792,000 after purchasing an additional 4,221 shares during the last quarter. Bank of New York Mellon Corp raised its stake in Harrow Health by 70.7% during the 4th quarter. Bank of New York Mellon Corp now owns 117,372 shares of the company’s stock valued at $913,000 after purchasing an additional 48,600 shares during the last quarter. Credit Suisse AG acquired a new position in Harrow Health during the 4th quarter valued at $738,000. Westside Investment Management Inc. acquired a new position in Harrow Health during the 1st quarter valued at $231,000. Finally, Jane Street Group LLC acquired a new position in Harrow Health during the 1st quarter valued at $149,000. Hedge funds and other institutional investors own 38.90% of the company’s stock.

Several analysts recently issued reports on the stock. TheStreet downgraded shares of Harrow Health from a “c-” rating to a “d” rating in a report on Thursday, May 28th. Zacks Investment Research raised shares of Harrow Health from a “sell” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Wednesday, June 10th. ValuEngine raised shares of Harrow Health from a “hold” rating to a “buy” rating in a report on Monday, May 11th. Finally, B. Riley decreased their price objective on shares of Harrow Health from $12.00 to $10.00 and set a “buy” rating for the company in a report on Tuesday, April 7th. Four equities research analysts have rated the stock with a buy rating, The company currently has an average rating of “Buy” and an average target price of $10.67.

Harrow Health Company Profile

Harrow Health, Inc owns a portfolio of healthcare businesses, primarily ophthalmology pharmaceutical compounding business, ImprimisRx, in the United States. It develops, produces, and sells medications, including ophthalmology focused compounding formulations; and sterile and non-sterile compounded medications to physicians and patients.

Further Reading: What are catch-up contributions?

Insider Buying and Selling by Quarter for Harrow Health (NASDAQ:HROW)

Receive News & Ratings for Harrow Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Harrow Health and related companies with MarketBeat.com's FREE daily email newsletter.